•
Sep 30, 2023

DexCom Q3 2023 Earnings Report

Reported solid financial results and advanced global access to Dexcom CGM.

Key Takeaways

Dexcom's Q3 2023 revenue grew by 27% year-over-year to $975.0 million. The company raised its full-year revenue and margin guidance and announced a $500 million share repurchase program.

Revenue grew 27% versus the same quarter of the prior year to $975.0 million.

U.S. revenue growth of 24% and international revenue growth of 33%.

GAAP operating income of $205.5 million or 21.1% of revenue.

Secured reimbursement for Dexcom ONE in France.

Total Revenue
$975M
Previous year: $770M
+26.7%
EPS
$0.5
Previous year: $0.28
+78.6%
Gross Margin
63.9%
Previous year: 64.2%
-0.5%
Operating Margin
21.1%
Previous year: 19.2%
+9.9%
Gross Profit
$623M
Previous year: $494M
+26.1%
Cash and Equivalents
$644M
Previous year: $698M
-7.8%
Free Cash Flow
$219M
Previous year: $185M
+18.3%
Total Assets
$6.6B
Previous year: $4.9B
+34.6%

DexCom

DexCom

DexCom Revenue by Segment

DexCom Revenue by Geographic Location

Forward Guidance

The company is increasing fiscal year 2023 guidance for Revenue, Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin, and Adjusted EBITDA Margin.

Positive Outlook

  • Revenue of approximately $3.575 - 3.600 billion (23-24% growth)
  • Non-GAAP Gross Profit Margin of approximately 64%
  • Non-GAAP Operating Margin of approximately 19%
  • Adjusted EBITDA Margin of approximately 28%

Revenue & Expenses

Visualization of income flow from segment revenue to net income